PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase InhibitorsMichael E. Stokes, David Surguladze, Eric S. Lightcap et al.|Clinical Cancer Research|2023Cited by 27
Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer modelsFeven Tameire, Nandita Bose, Maria Fumagalli et al.|Cancer Research|2023Cited by 3